ANTIBODY THERAPEUTICS XCHANGE
WEST COAST
San Francisco
September 25, 2023

Welcome to hubXchange’s Antibody Therapeutics Xchange West Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.

Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: DoubleTree by Hilton San Francisco Airport, 835 Airport Blvd, Burlingame CA 94010-9949

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Target Selection

Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer
Challenges in the development of regenerative therapies in age-related chronic diseases
Strategies and considerations of discovering antibodies against novel targets

Track 2: Lead Identification & Optimization

Antibody discovery strategies and optimization
HT screening and characterization assays

Track 3: Formats & Scaffolds

Using antibody-based modalities to remove pathogenic cell populations in non-oncology indications
Considerations for CAR-T/CAR-NK Cell binder format designs during screening and selections
Fc engineering for improved antibody drug ability

Track 4: Bi/Multi-Specifics

Application of computer aided design (CAAD) for therapeutic antibody development
Bi/tri-specific strategies for overcoming cell engager toxicity
CMC challenges of bi/multi specifics

Track 5: Emerging Technologies

CDR-H3 repertoire for antibody discovery
Next-generation platforms – Utilizing combinations of invitro, in vivo and in silico methods

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Bispecific antibodies have the potential to unlock novel biology and elicit unique functionalities. ADS strategies for engineering bispecific antibodies with favorable functional and early developability profiles using target binders derived from immunizing AlivaMab® Mouse will be highlighted by case studies describing the engineering of dual-agonist and antagonist bispecific antibodies capable of selectively triggering function only when bound to two target antigens simultaneously

Ankita Srivastava

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

Ankita has over 15 years of experience in drug discovery and preclinical development. Prior to AlivaMab Discovery Services, Ankita was VP, Antibody Engineering and Protein Sciences at Ichnos Therapeutics. Ankita has led projects across diverse therapeutic areas and enabled biologics design, production, characterization and preclinical development resulting in several candidate molecules in clinic.

09:05 – 10:05

Considerations and challenges of target selection for antibody therapeutics in oncology

Specificity of target antigens
Matching target with appropriate drug modality tumour heterogeneity
Consideration of combination targets for multi-specifics

Alexander Martinko

Director of Antibody Engineering, Cartography Biosciences

Alex Martinko is a protein engineer, chemical biologist, and biotech entrepreneur working to translate new technologies into next generation therapies. Currently he is co-founder and Sr. Director of Protein Engineering at Soteria Biotherapeutics where he is leading up the development of their T-LITE™ T-cell engager platform. Prior to Soteria, Alex completed his PhD in the lab of Jim Wells at UCSF, where he gained expertise in antibody engineering, chemical biology, proteomics, and cancer cell signalling.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Lead Identification & Optimization: Generating drug-like antibodies from in vitro platforms

What constitutes a drug-like antibody?
Can one generate drug-like antibodies from an in vitro platform?
What are the preferred antibody discovery platforms – in vitro vs in vivo antibody discovery? And why?
What sorts of affinities and diversities can be expected from in vitro platforms?
Can in vitro platforms be used to improve antibody affinities and developability?

Fortunato Ferrara

VP Antibody Discovery, Specifica

Fortunato Ferrara has almost two decades in experience in recombinant antibody engineering and molecular immunology, mostly focused on antibody discovery using phage and yeast display platform.

Currently he serves as Vice President of Discovery Service as Specifica where he leads a team focused on selecting recombinant antibodies from the semi-synthetic Specifica proprietary libraries. His group continues to improve selection strategies against challenging targets or to obtain antibodies with very specific features.

Before joining Specifica, he was an Assistant Research Professor in Experimental Therapeutica at the Comprehensive Cancer Center of the University of New Mexico in Albuquerque. Previously, he was a postdoctoral fellow in the laboratory of Andrew Bradbury, at the Los Alamos National Laboratory. He has over 40 publications (https://www.ncbi.nlm.nih.gov/myncbi/10iXcmu0aj9/bibliography/public/) and he is co-inventor on several patents and patent applications.

He holds a PhD in Molecular Medicine and B.S. in Molecular Biology from the University of Trieste in Italy.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

As the field of antibody drug development advances with novel technologies such as AI-designed molecules and bispecific antibodies (bsAbs), new challenges in research-phase production have arisen. This presentation showcases WuXi Biologics’ five innovative antibody production platforms: Ultra 96, 7-7-7, Quick’n Clean, Premium BsAb, and GramExpress. Each platform is designed to meet specific challenges presented by the latest trends in antibody drug research. Our solutions encompass ultra-high throughput, small-scale antibody production ideal for rapidly producing a large number of targets like AI-designed molecules, cost-effective identification of optimal bsAb pairings, and streamlined scale-up production for various types of antibodies.

Jiansheng Wu

Head of Protein Sciences, Vice President, WuXi Biologics

Jiansheng Wu is the Head of Protein Sciences and Vice President at WuXi Biologics. With vast experience and expertise in protein sciences, he has been instrumental in establishing global protein production facilities and developing world-leading protein production technologies and platforms. Having participated in over 50 drug development projects, Jiansheng is a leading authority in automated expression, purification, and characterization of diverse proteins, from antibodies and antigens to enzymes and complex proteins. Previously at Genentech for 15 years, he made significant contributions to innovative protein expression and purification technologies.

13:50 – 14:20

1-2-1 Meetings / Networking Break

14:20 – 14:50

1-2-1 Meetings / Networking Break

14:50 – 15:20

Poster Session:

Lead Identification & Optimization topic: The future of developability profiling: AI-driven in silico immunogenicity screening and high throughput in vitro characterization

Antibody developability is a critical aspect of the drug discovery process that refers to the ability of an antibody to be developed into a safe, effective, and marketable therapeutic. IPA’s high throughput in silico and in vitro workflows allow for early comprehensive triage and lead candidate optimization. LENSᵃⁱ™ Integrated Intelligence Technology from BioStrand®, an IPA
subsidiary, powers the in silico immunogenicity screening workflow. By leveraging data from
over 1,800 clinical benchmarks, this workflow provides 3D structural models depicting each
candidate’s immunogenicity composite ranking from HLA binding predictions based on customizable phenotype distribution and humanness scoring referencing the complete human proteome. By combining over 12 in vitro assays with the in silico immunogenicity screening outputs, IPA provides a comprehensive data package that saves time and money while also
reducing risks in both clinical and post-commercialization phases.

Barry Duplantis

VP Client Relations & Business Development, ImmunoPrecise Antibodies

Barry Duplantis serves as Vice President of Client Relations and Business Development (BD)
for IPA and is responsible for managing and coordinating all sales and BD related activities. He is a scientific entrepreneur and business development specialist with over 10 years of experience
in the commercial application of drug and vaccine discovery platforms. Prior to his appointment to VP of Client Relations & BD, he served as the Director of Client Relations for IPA (Canada) and
was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

15:20 – 15:30

Afternoon Refreshments

15:30 – 16:00

1-2-1 Meetings / Networking Break

16:10 – 17:10

Developing second-generation therapeutic after a clinical failure

How to have stakeholders support after a failure?
Do we really know why it failed?
Can we use mouse models for human toxicity?

Marco Muda

Vice President, Hengenix

17:10 – 18:10

Evening Drinks Reception

Lead Identification & Optimization

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Ankita Srivastava

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

09:05 – 10:05

HT screening and characterization assays

What are your favorite developability assays and why?
How do you approach triaging during early library screening?
What are your thoughts on affinity? Is tighter always better? How weak is too weak to be a
drug?
How do you balance function vs developability?
Do you have a different approach based on the source of the antibody such as a human, mouse, rat, rabbit, phage, llama etc.?
What are the unique challenges that each type of discovery platform presents?

Kendra Avery

Associate Director, Bioanalytical and Biophysical Characterization, Xencor

Kendra Avery graduated with her Ph.D. in chemistry from The Pennsylvania State University working on bio-templated nanomaterial synthesis. Afterwards she shifted focus to begin a postdoc at The City of Hope Cancer Research Center with an emphasis on structural biology and biophysical characterization of therapeutic antibodies, antibody binding proteins, and peptides. Kendra translated her postdoctoral experience into a career at Xencor where she was able to build the Biophysical Characterization team within the Protein Sciences & Technology Department. Kendra loves thinking about kinetics, looking at beautiful sensorgrams, maximizing efficiency, and loves dogs of all shapes and sizes.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Early immunogenicity risk assessment and functional testing of biotherapeutics

In silico and in vitro immunogenicity assessment as a de-risking strategy
In vitro assessment of innate responses
The power of a combined approach
In vitro Functional testing of lead candidates

Sofie Pattyn

CTO and founder, ImmunXperts

Sofie has over 25 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immune-oncology and Cell and Gene Therapy products. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

Jiansheng Wu

Head of Protein Sciences, Vice President, WuXi Biologics

13:50 – 14:20

1-2-1 Meetings / Networking Break

14:20 – 14:50

1-2-1 Meetings / Networking Break

14:50 – 15:20

Poster Session:

A case study on flexibility: Evitria’s bespoke solutions for lead selection and optimization

High quality research. Fast timelines. And within budget. As a scientist or research leader, you’re often only allowed two out of these three options. But what if you could have all three?

Utilizing evitria’s bespoke workflow solutions supports preclinical research of any stage, with any format, and at any scale greater than 1-mg.
Reliable production with a great support team allows evitria to tailor each project and ensure that your material reaches you the way you need it and when you need it.
With over 120,000 successful antibody production runs, evitria’s materials have helped teams to enter clinical trials and successfully commercialize. Let our 13-year history of focused services help your research to advance as well.

Dylan Brethour

Senior Account Manager, Evitria

Dylan Brethour is a Senior Account Manager at Evitria AG, a company whose mission is to provide the highest quality, research-grade antibody and protein reagents to support antibody therapeutic developers. Dylan joined evitria in June 2023 with a background supporting biotechnology and pharmaceutical companies through antibody sequencing and characterization services, and more widely supporting research teams as a life sciences reagent provider. Dylan holds a Master of Science in Laboratory Medicine and Pathobiology from the University of Toronto and a Bachelor of Science with Joint Honours in Biomedical Sciences and Psychology from the University of Waterloo.

15:20 – 15:30

Afternoon Refreshments

15:30 – 16:00

1-2-1 Meetings / Networking Break

16:10 – 17:10

Antibody optimization strategies

Co-optimization of multiple criteria (eg, potency and developability)
Optimization against challenging targets (eg, glycans or hard to make proteins)
Choice of approach (eg, display-based selection or semi-rational designed variants)

Shaun Lippow

Vice President, Drug Discovery & Protein Engineering, Atreca, Inc

Shaun is Vice President of Drug Discovery & Protein Engineering at Atreca, Inc, where his responsibilities include antibody lead optimization, development of multispecific therapeutics, and elucidation of the targets of Atreca’s novel patient-derived antibodies. He has been engineering antibodies, bispecifics, fusion-protein therapeutics, and enzymes for 20 years, combining structure-based modeling with high-throughput display methods as needed. Prior to Atreca, his experience includes leading a protein technologies group at Bayer HealthCare, heading research at Silver Creek Pharmaceuticals, and helping spin out startups from leading academic labs.

17:10 – 18:10

Evening Drinks Reception

Formats & Scaffolds

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Ankita Srivastava

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

09:05 – 10:05

Using antibody-based modalities to remove pathogenic cell populations in non-oncology indications

Can the immuno-oncology toolbox be repurposed to target non-malignant cells in chronic diseases (e.g. autoimmune, inflammatory, fibrosis)?
What antibody-based modalities are most appropriate for eliminating non-malignant cell populations and establishing therapeutic window?
What on- and off-target toxicities are likely to arise and how can these risks be mitigated?

Adam Freund

Chief Executive Officer, Arda Therapeutics

Adam is the founder and CEO of Arda Therapeutics, a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Dr. Freund has 18 years of experience in life science research and development, focused on blending experimental and computational biology to understand and modulate age-related diseases. Previously, he was a Principal Investigator at Calico, where he founded an R&D lab and initiated and drove multiple therapeutics programs. His research works span >20 peer-reviewed publications and >8,000 citations. He received his PhD from UC Berkeley and his postdoc from Stanford.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Lead Identification & Optimization topic: How to expand diversity of antibody repertoire and maximize therapeutic lead candidates

How different antibody development platforms affect antibody diversity
How Rabbit vs. Mouse host affect antibody diversity
How to screen out lead candidate clones as early and efficiently as possible?
Linear expression module (LEM) vs. traditional plasmid expression
Humanization and other antibody engineering

Rosa Zhu

Lead Application Scientist, AbClonal Technology

Jiuhe (Rosa) Zhu, Ph.D. is the lead application scientist at ABclonal Technology. Dr. Zhu obtained extensive research experience in antibody application and production from nearly 10 years of industrial and academic experience in molecular biology, physiology, neuroscience, and antibody discovery. Since 2021, she has successfully designed and delivered more than 300 custom antibody development projects, including polyclonal antibodies and monoclonal antibodies. During her academic career, she worked as a postdoc researcher at Northwestern University, where she studied different proteoforms of amyloid-beta in Alzheimer’s disease. She holds a PhD in Molecular and Integrative Physiology from University of Illinois at Urbana-Champaign.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

Jiansheng Wu

Head of Protein Sciences, Vice President, WuXi Biologics

13:50 – 14:20

1-2-1 Meetings / Networking Break

14:20 – 14:50

1-2-1 Meetings / Networking Break

14:50 – 15:20

Poster Session:

Lead Identification & Optimization topic: Pioneer: a novel biotherapeutic antibody discovery platform

The Pioneer Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic discovery. The Pioneer Platform comprises a new antibody phage display library engineered to have optimal properties for the selection of therapeutic candidates, including the reduction of CDR-located posttranslational modification sites for improved developability. With 92% of the clones (VH and VL combined) encoding functional antibodies, the Pioneer Antibody Library encodes 2.25×1011 unique antibodies. Pioneer takes advantage of SpyDisplay, a novel selection system based on SpyTag technology. Herein, we demonstrate that the Pioneer Platform delivers diverse high-affinity antibody lead candidates. Using anti-TIGIT antibodies, we show that the performance of our lead candidates is comparable with antibodies undergoing clinical trials.

Birthe Jessen-Park

Technical Sales Specialist – Custom Antibody Content Division, Bio-Rad

Birthe is a technical sales specialist for Bio-Rad’s Custom Antibody Service and supports customers leveraging Bio-Rad’s innovative Pioneer Antibody Discovery Platform for their biotherapeutic discovery campaigns. Prior to joining Bio-Rad, she gained several years of experience in antibody discovery as an Associate Director at Alloy Therapeutics, where she led the In vivo Antibody Discovery team, and proceeding that as a Scientist in Antibody Discovery and Protein Engineering at Medimmune. She received her PhD from the University of Freiburg, Germany and completed her postdoctoral training at the University of California, San Francisco.

15:20 – 15:30

Afternoon Refreshments

15:30 – 16:00

1-2-1 Meetings / Networking Break

16:10 – 17:10

Early screening and assessment of bi/multivalent and multifunctional antibody molecules

• What are strategies for determining simultaneous target engagement? Are there specific techniques or emerging technologies that are critical in early screening?
• How can avidity effects be quantitatively assessed and used to predict potency?
• With many molecular formats available, how is the optimal format chosen? How can the choice of molecular format influence function, developability and manufacturability?

Kevin Lindquist

Executive Director, Loxo Oncology

Kevin Lindquist has over 20 years of experience in the biotechnology industry. His early experience includes research related to diffusion and flow phenomena in biosensor devices, nanoparticle-based targeted drug delivery, and characterization of biomolecular interactions. Kevin has 8 years of experience as a field application scientist for Biacore Inc./GE Lifesciences – a pioneer in real-time label-free biosensor instrumentation. He spent 12 years as a member of protein engineering groups at Pfizer where he managed a biosensor core facility and participated in numerous collaborations related to antibody engineering and technology. He currently is an Executive Director of Biophysical Chemistry at Loxo@Lilly.

17:10 – 18:10

Evening Drinks Reception

Bi/Multi-Specifics

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Ankita Srivastava

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

09:05 – 10:05

Identifying developable formats and components for multi-specifics

What antibody formats are best suited as components in complex multi-specifics? (e.g., VHH, scFv, Fab, native protein domain)
Given a limited experimental budget, how do you balance multiple binding domain candidates with multiple format candidates?
Can computational tools be used to narrow the search space of developable candidates?

Rishi Bedi

Chief Executive Officer, Y-Trap

Rishi Bedi is Chief Executive Officer of Y-Trap, where he leads development of novel multifunctional therapeutics for immuno-oncology focused on correcting the dysfunctional tumor-immune microenvironment. Previously, he worked on broad-spectrum vaccines at Centivax, machine learning for neuro drug discovery at Herophilus, and antibody repertoire analysis at Distributed Bio. He studied AI and machine learning at Stanford.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Lead Identification & Optimization topic:

Modern challenges in biologics drug discovery and development

Challenging targets and challenging project design goals: Key gaps in discovery and engineering
Narrowing down potential candidates: How early is too early to screen for developability, and immunogenicity?
AI and ML in Biologics drug discovery: Myths versus reality

Jane Seagal

Vice President, Antibody Discovery, AlivaMab Discovery Services

Jane has over a decade of experience in antibody drug discovery using in vivo approaches. Prior to joining AlivaMab Discovery Services, Jane led the In Vivo Antibody Discovery team at AbbVie, where she introduced and implemented multiple technology platforms, including hybridoma automation and direct antibody cloning from human patient samples. Jane has led projects across diverse therapeutic areas and enabled antibody discovery campaigns resulting in several clinical candidate molecules.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

Jiansheng Wu

Head of Protein Sciences, Vice President, WuXi Biologics

13:50 – 14:20

1-2-1 Meetings / Networking Break

14:20 – 14:50

1-2-1 Meetings / Networking Break

14:50 – 15:20

Poster Session:

A platform for tuning therapeutic Efficacy of T-Cell-Engaging Bispecific Antibodies

T-cell activation requires appropriate strength of stimulation and costimulation. Blocking coinhibitory pathways prevents T-cell exhaustion and escape. Here, we present diverse panels of lead-quality antibodies, including antibodies against CD3 and PD-L1, ready for reformatting into advanced modalities for the development of finely tuned multi-drug approaches against a variety of tumor targets. We demonstrate that in bispecific contexts these antibodies are biologically active and have favorable biophysical properties

Jane Seagal

Vice President, Antibody Discovery, AlivaMab Discovery Services

15:20 – 15:30

Afternoon Refreshments

15:30 – 16:00

1-2-1 Meetings / Networking Break

16:10 – 17:10

How to design CMC-friendly bi/multi-specific molecules to enable fast FIH development

The goal is to connect discovery and CMC to bring up awareness of CMC challenges that could be fixed earlier in molecule design
Collect opinions on major challenges of CMC development of bi/multi-specific constructs: e.g., cell line selection, bioprocess challenge of removing misassembled forms, formulation and analytical challenge of characterizing degradants and impurities
Discuss strategies to capture CMC risks earlier in development, e.g., screen approaches, stress models

Yi Li

Director, Biologics CMC Drug Product Development, AbbVie

Li Yi, Ph.D., is a director of formulation development at the Bay Area site of AbbVie with 14 years of industrial experience in pharmaceutical development of biologics including bi and multi-specifics molecules and other protein modalities. Before this role, she worked at Genentech as a scientist and group leader. She received a B.S. in Chemistry from Fudan University in Shanghai and a Ph.D. in Chemistry from the University of Michigan – Ann Arbor.

17:10 – 18:10

Evening Drinks Reception

Emerging Technologies

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation:

Overcoming challenges in engineering selectively functional agonist and antagonist bispecific therapeutic antibodies

Ankita Srivastava

Vice President, Antibody Engineering and Protein Sciences, AlivaMab Discovery Services

09:05 – 10:05

Multispecific and T cell engagers (discovery/development)

• What technological shortcomings effect your entry and progress towards bi/multispecific target selection and appropriate format selection?
• What role do technologies play in insuring proper epitope specificity recognition of bi/multispecifics?
• What common challenges need to be addressed with non-canonical components like single domain antibodies and other binding scaffolds?
• What is the opportunities and limitations for bi/multispecifics that utilize cytokine component(s) and what is necessary for their expanded utility?
• What complexities exist in area of safety assessment of bi/multispecifics and what further needs remain to be addressed or simplified?

Ramesh Bhatt

Vice President – Discovery Biology and Translational Research, Protagonist

Ramesh Bhatt, PhD, is Vice President, Discovery Biology and Translational Research at Protagonist Therapeutics. Prior to Protagonist Ramesh was VP and scientific founder in charge of establishing the bispecific platform and portfolio of Janux Therapeutics (NASD:JANX). Ramesh has held research leadership roles at Rigel (NASD:RIGL), Sea Lane Biotechnology (acquired by i2 Pharmaceuticals), Bioren (acquired by Pfizer), after beginning his career at Eli Lilly. Ramesh has been a consultant to Pharma, Venture Capital, and advisor to public and private biotech companies. Ramesh received his bachelors from Southern Illinois University, PhD from Stanford University, and was a postdoctoral fellow at Northwestern University.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

New Advancements in Antibody Production for Research

Jiansheng Wu,

Head of Protein Sciences, Vice President, WuXi Biologics

13:50 – 14:20

1-2-1 Meetings / Networking Break

14:20 – 14:50

1-2-1 Meetings / Networking Break

14:50 – 15:20

Poster Session:

A new generation of 1M NaOH base stable Protein A products for antibody purification

Modern antibody purification relies heavily on the use of Protein A solid phases. As these are generally quite expensive, reusability is critical and sodium hydroxide is the cleaning agent of choice.
emp BIOTECH has developed a new range of solid phases that tolerate 1 M sodium hydroxide in excess of 100 cycles with minimal loss in binding capacity. In this poster we will provide information on the solid phases for both clarified and unclarified feed streams and the formats in which they are offered, including SMART Chromatography™

Alistair Hurst

General Manager (USA) & Business Development Director (Global), EMP Biotech

Alistair Hurst is the General Manager at emp BIOTECH’s subsidiary in the USA. For more than 30 years he has been active in the downstream processing sector and has developed a number of purification technologies to improve purification performance.

15:20 – 15:30

Afternoon Refreshments

15:30– 16:00

1-2-1 Meetings / Networking Break

16:10 – 17:10

CDR-H3 repertoire for antibody
discovery

CDR3 length and influence on binding
CDR3 variability on charge distribution
CDR3 influenced aggregation

Sastri Palla

Principal Scientist, TrueBinding

Over 12 years of experience in complex hypothesizing, experimental design and problem-solving in critical drug discovery and allied life sciences. Result oriented, business first scientist with deep expertise in Virology and Cancer Biology for targeted therapy in the Pharmaceutical industry. Over the years I am frequently recognized for effective collaboration with cross-functional teams. Strong experience in scoping, budgeting and competitor analysis related to the Pharmaceutical industry. Worked as a science consultant for two ventures and helped increase their business.

17:10 – 18:10

Evening Drinks Reception

ANTIBODY THERAPEUTICS XCHANGE
WEST COAST
San Francisco
September 25, 2023

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Target Selection

Lead Identification & Optimization

Formats & Scaffolds

Bi/Multi-Specifics

Emerging Technologies

Partners

© Copyright 2023 by Weblify & Webtec

ANTIBODY THERAPEUTICS XCHANGEWEST COASTSan FranciscoSeptember 25, 2023

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Target Selection

Lead Identification & Optimization

Formats & Scaffolds

Partners

ANTIBODY THERAPEUTICS XCHANGE
WEST COAST
San Francisco
September 25, 2023